{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:01:50Z","timestamp":1780412510906,"version":"3.54.1"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000730","name":"Museums Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>TOURMALINE\u2010MM1 is a phase III, randomized, double\u2010blind, placebo\u2010controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo\u2010Rd in patients with relapsed\/refractory multiple myeloma following 1\u20133 prior lines of therapy. The study met its primary endpoint, demonstrating significantly longer progression\u2010free survival (PFS) in the IRd arm versus placebo\u2010Rd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, <jats:italic>P<\/jats:italic>\u2009=\u2009.01), with limited additional toxicity. Patient\u2010reported health\u2010related quality of life (HRQoL) was a secondary endpoint of TOURMALINE\u2010MM1. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core\u201030 (QLQ\u2010C30) and Multiple Myeloma Module 20 (QLQ\u2010MY20) were completed at screening, the start of cycles 1 and 2, every other cycle, the end of treatment, and every 4 weeks until progression. Over median follow\u2010up of 23.3 and 22.9 months in the IRd and placebo\u2010Rd arms, mean QLQ\u2010C30 global health status (GHS)\/QoL scores were maintained from baseline over the course of treatment in both groups, with no statistically significant differences between groups. EORTC QLQ\u2010C30 function domain scores were also generally maintained from baseline; similarly, physical, emotional, and social function domains were maintained with IRd versus placebo\u2010Rd, with slightly higher mean change from baseline scores at earlier time points with IRd. Findings from this double\u2010blind study demonstrate that addition of ixazomib to Rd significantly improved efficacy while HRQoL was maintained, reflecting the limited additional toxicity seen with IRd versus placebo\u2010Rd, and support the feasibility of long\u2010term IRd administration.<\/jats:p>","DOI":"10.1002\/ajh.25134","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T08:59:04Z","timestamp":1525424344000},"page":"985-993","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Patient\u2010reported health\u2010related quality of life from the phase III TOURMALINE\u2010MM1 study of ixazomib\u2010lenalidomide\u2010dexamethasone versus placebo\u2010lenalidomide\u2010dexamethasone in relapsed\/refractory multiple myeloma"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"first","affiliation":[{"name":"Department of Haematology Hospital La Mil\u00e9trie, and INSERM CIC 1402 Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, St. Istv\u00e1n and St. L\u00e1szl\u00f3 Hospital, 3rd Department of Internal Medicine Semmelweis University Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Southern Alberta Cancer Research Institute, University of Calgary Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Viterbo","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Onco\u2010Hematologia, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Entidade P\u00fablica Empresarial (IPOPFG, EPE) Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartrum","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Haematology Palmerston North Hospital Palmerston North Manawatu New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gimsing","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[{"name":"4<sup>th<\/sup> Department of Medicine \u2010 Hematology University Hospital Hradec Kralove Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Samoilova","sequence":"additional","affiliation":[{"name":"Nizhnii Novgorod Region Clinical Hospital Nizhnii Novgorod Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Department of Hematology University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Langer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III University Hospital of Ulm Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Hematology University of British Columbia Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Hematology Tochigi Cancer Center, Utsunomiya Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cleeland","sequence":"additional","affiliation":[{"name":"Department of Symptom Research University of Texas M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao Mark","family":"Lin","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Skacel","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"},{"name":"Department of Hematology Charles University General Hospital Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital H\u00f4tel Dieu Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Millennium Pharmaceuticals Incorporated. NINLARO\u00ae (ixazomib) capsules for oral use. Prescribing information 2015. Takeda Pharmaceuticals Limited; 2015."},{"key":"e_1_2_8_3_1","unstructured":"Takeda. Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO (ixazomib) the First Oral Proteasome Inhibitor for Use in Patients with Multiple Myeloma;2016.https:\/\/www.takeda.com\/news\/2016\/20160916_7564.html."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_8_5_1","unstructured":"National Cancer Institute. Bethesda M. SEER Cancer Stat Facts: Myeloma;2017.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01250.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-4441.2003.00195.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1021772"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01303.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112557"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.05.007"},{"key":"e_1_2_8_19_1","unstructured":"United States Food and Drug Administration. Guidance for Industry: Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims;2009http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM193282.pdf."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01665.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9648"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.06.001"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28274"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1841-y"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.12.007"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120028504"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1224-1"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.01.010"},{"key":"e_1_2_8_38_1","unstructured":"EMA. Guideline on the evaluation of anticancer medicinal products in man;2017.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2017\/11\/WC500238764.pdf."},{"key":"e_1_2_8_39_1","unstructured":"EMA. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies;2014.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2016\/04\/WC500205159.pdf."},{"key":"e_1_2_8_40_1","unstructured":"EMEA. Reflection paper on the regulatory guidance for the use of HRQL measures in the evaluation of medicinal products;2005.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003637.pdf."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-41"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T18:57:34Z","timestamp":1692471454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/ajh.25134"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25134","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"2017-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}